86 related articles for article (PubMed ID: 19237273)
21. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.
Sekulić A; Hudson CC; Homme JL; Yin P; Otterness DM; Karnitz LM; Abraham RT
Cancer Res; 2000 Jul; 60(13):3504-13. PubMed ID: 10910062
[TBL] [Abstract][Full Text] [Related]
22. B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer.
Tan J; Lee PL; Li Z; Jiang X; Lim YC; Hooi SC; Yu Q
Cancer Cell; 2010 Nov; 18(5):459-71. PubMed ID: 21075311
[TBL] [Abstract][Full Text] [Related]
23. mTOR and cancer therapy.
Easton JB; Houghton PJ
Oncogene; 2006 Oct; 25(48):6436-46. PubMed ID: 17041628
[TBL] [Abstract][Full Text] [Related]
24. Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.
Crowder RJ; Ellis MJ
Breast Cancer Res; 2005; 7(5):212-4. PubMed ID: 16168140
[TBL] [Abstract][Full Text] [Related]
25. The mammalian target of rapamycin-signaling pathway in regulating metabolism and growth.
Yang X; Yang C; Farberman A; Rideout TC; de Lange CF; France J; Fan MZ
J Anim Sci; 2008 Apr; 86(14 Suppl):E36-50. PubMed ID: 17998426
[TBL] [Abstract][Full Text] [Related]
26. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment.
Jozwiak J; Jozwiak S; Oldak M
Med Res Rev; 2006 Mar; 26(2):160-80. PubMed ID: 16329102
[TBL] [Abstract][Full Text] [Related]
27. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.
Kenerson H; Dundon TA; Yeung RS
Pediatr Res; 2005 Jan; 57(1):67-75. PubMed ID: 15557109
[TBL] [Abstract][Full Text] [Related]
28. Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome.
Kaylani S; Theos AJ; Pressey JG
Pediatr Dermatol; 2013; 30(6):e194-7. PubMed ID: 23316753
[TBL] [Abstract][Full Text] [Related]
29. Targeting mTOR with rapamycin: one dose does not fit all.
Foster DA; Toschi A
Cell Cycle; 2009 Apr; 8(7):1026-9. PubMed ID: 19270529
[TBL] [Abstract][Full Text] [Related]
30. Angiosarcoma successfully treated with liver transplantation and sirolimus.
Xue M; Masand P; Thompson P; Finegold M; Leung DH
Pediatr Transplant; 2014 Jun; 18(4):E114-9. PubMed ID: 24641525
[TBL] [Abstract][Full Text] [Related]
31. Rapamycin treatment at immunosuppressive doses affects tumor blood vessel circulation.
Koehl G; Guba M; Seeliger H; Steinbauer M; Anthuber M; Jauch KW; Geissler EK
Transplant Proc; 2003 Sep; 35(6):2135-6. PubMed ID: 14529865
[No Abstract] [Full Text] [Related]
32. ACTL6A Promotes the Proliferation of Esophageal Squamous Cell Carcinoma Cells and Correlates with Poor Clinical Outcomes.
Li RZ; Li YY; Qin H; Li SS
Onco Targets Ther; 2021; 14():199-211. PubMed ID: 33469301
[TBL] [Abstract][Full Text] [Related]
33. Translation Stress Regulates Ribosome Synthesis and Cell Proliferation.
Vadivel Gnanasundram S; Fåhraeus R
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486342
[TBL] [Abstract][Full Text] [Related]
34. Sirolimus Ointment for Facial Angiofibromas in Individuals with Tuberous Sclerosis Complex.
Amin S; Lux A; Khan A; O'Callaghan F
Int Sch Res Notices; 2017; 2017():8404378. PubMed ID: 29270462
[No Abstract] [Full Text] [Related]
35. Ribosomal proteins: insight into molecular roles and functions in hepatocellular carcinoma.
Xie X; Guo P; Yu H; Wang Y; Chen G
Oncogene; 2018 Jan; 37(3):277-285. PubMed ID: 28945227
[TBL] [Abstract][Full Text] [Related]
36. Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer.
Chen B; Tan Z; Gao J; Wu W; Liu L; Jin W; Cao Y; Zhao S; Zhang W; Qiu Z; Liu D; Mo X; Li W
J Exp Clin Cancer Res; 2015 Oct; 34():126. PubMed ID: 26490682
[TBL] [Abstract][Full Text] [Related]
37. A liaison between mTOR signaling, ribosome biogenesis and cancer.
Gentilella A; Kozma SC; Thomas G
Biochim Biophys Acta; 2015 Jul; 1849(7):812-20. PubMed ID: 25735853
[TBL] [Abstract][Full Text] [Related]
38. SDF-1/CXCL12 induces directional cell migration and spontaneous metastasis via a CXCR4/Gαi/mTORC1 axis.
Dillenburg-Pilla P; Patel V; Mikelis CM; Zárate-Bladés CR; Doçi CL; Amornphimoltham P; Wang Z; Martin D; Leelahavanichkul K; Dorsam RT; Masedunskas A; Weigert R; Molinolo AA; Gutkind JS
FASEB J; 2015 Mar; 29(3):1056-68. PubMed ID: 25466898
[TBL] [Abstract][Full Text] [Related]
39. The miR-126-VEGFR2 axis controls the innate response to pathogen-associated nucleic acids.
Agudo J; Ruzo A; Tung N; Salmon H; Leboeuf M; Hashimoto D; Becker C; Garrett-Sinha LA; Baccarini A; Merad M; Brown BD
Nat Immunol; 2014 Jan; 15(1):54-62. PubMed ID: 24270517
[TBL] [Abstract][Full Text] [Related]
40. PEComa of the colon resistant to sirolimus but responsive to doxorubicin/ifosfamide.
Scheppach W; Reissmann N; Sprinz T; Schippers E; Schoettker B; Mueller JG
World J Gastroenterol; 2013 Mar; 19(10):1657-60. PubMed ID: 23539498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
